Heartflow, Inc. - Common Stock (HTFL)

Heartflow (NASDAQ:HTFL) reported second-quarter revenue of $64.1 million, up 48% from a year earlier, as growth in its Plaque Analysis offering, durable FFR-CT utilization and continued expansion of the coronary CT angiography, or CCTA, market supported results. U.S. revenue rose 51% to $59.6 milli

HeartFlow (NASDAQ:HTFL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to

The medical technology company reported a notable insider sale in recent filings.

Heartflow boasts rapid AI-driven growth but faces reimbursement headwinds, while Omeros bets everything on its first commercial launch.

Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.

AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.

HeartFlow delivers AI-powered, non-invasive cardiac diagnostics for hospitals and cardiology clinics using proprietary imaging technology.

Heartflow (NASDAQ:HTFL) reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its Plaque Analysis product and continued expansion of the coronary CT angiography, or CCTA, market. Pres

Heartflow and Neptune Insurance deserve a closer look.

HeartFlow provides AI-driven tools for non-invasive heart diagnostics, serving hospitals and clinics with advanced cardiovascular insights.

HeartFlow delivers AI-powered cardiac diagnostics to hospitals worldwide; a key insider recently trimmed their stake, SEC filings show.

HeartFlow delivers AI-powered, non-invasive cardiac diagnostics to healthcare providers seeking advanced imaging and decision support tools.

CEO Brent Ness noted a broad global market, with approximately 266 million people affected by chronic low back pain.

AI-powered cardiac diagnostics firm HeartFlow reported a recent insider buy, as disclosed in the latest SEC filing.

A key FDA-cleared analysis tool earned professional accolades for its utility.

One family office fund just made Karman its biggest reported equity bet—here’s what long-term investors should take from the move.

A billionaire family office has made a big bet on a newly public AI-driven heart diagnostics company—here’s what long-term investors should take from the move.

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Bain Capital completely exited its position in Disc Medicine stock during the third quarter